Paeds SAQs · paediatric-dermatology
Genodermatoses and neurocutaneous skin findings — formative SAQs
Formative SAQs on paediatric genodermatoses and neurocutaneous syndromes: the recognition and stepwise surveillance of a child with neurofibromatosis type 1 — café-au-lait macules, skinfold freckling, the NIH diagnostic criteria, optic pathway glioma and blood pressure surveillance, and the malignant peripheral nerve sheath tumour red flag — and the recognition and management of an infant with tuberous sclerosis complex presenting with infantile spasms and a subependymal giant cell astrocytoma, covering vigabatrin, everolimus and the major-minor diagnostic criteria.
On this page & tools
Target exams
Question 1 (10 marks, 15 minutes)
A four-year-old girl is referred because her teacher has noticed multiple flat brown patches on her skin and some difficulty with reading. On examination she has seven café-au-lait macules between six and twelve millimetres across, freckling in both axillae, and three small soft flesh-coloured nodules on the trunk. Her mother has a few café-au-lait macules and a facial plexiform swelling. Her blood pressure is normal. [1] [6]
(a) What is the most likely diagnosis and which diagnostic criteria confirm it? (4 marks)
The most likely diagnosis is neurofibromatosis type 1. The National Institutes of Health consensus criteria are met by two or more of the following, and this child has several: six or more café-au-lait macules of at least five millimetres before puberty, axillary freckling, two or more neurofibromas, and an affected first-degree relative (her mother). [1] [6]
(b) Outline the surveillance this child needs. (4 marks)
Surveillance is in a medical home and covers vision (at least annual assessment for the optic pathway glioma through the early school years, with dedicated imaging for any visual change or precocious puberty), blood pressure (annual, for renal artery stenosis and phaeochromocytoma), growth and puberty, skin and plexiform lesion assessment, and developmental, learning and behavioural surveillance. Routine brain imaging is not required in the asymptomatic child. [2] [6]
(c) What would prompt urgent referral of one of her skin lesions, and what diagnosis must be excluded? (2 marks)
A plexiform lesion that grows rapidly, becomes painful or firm, or produces a new neurological deficit must be referred urgently for imaging and biopsy to exclude a malignant peripheral nerve sheath tumour, because early recognition of this aggressive tumour changes the outcome. [2] [6]
Question 2 (10 marks, 15 minutes)
A six-month-old boy with known tuberous sclerosis complex, diagnosed after a cardiac rhabdomyoma in the newborn period, presents with clusters of sudden flexion spasms in series, each with a brief tonic stiffening. His mother thinks he has lost some social smiling. An electroencephalogram shows a hypsarrhythmic pattern. [4] [3]
(a) What is the seizure type and what is the first-line treatment? (3 marks)
The child has epileptic (infantile) spasms with hypsarrhythmia. Vigabatrin is the first-line agent for infantile spasms in tuberous sclerosis complex, started promptly once the diagnosis is confirmed, with ophthalmology surveillance for the irreversible visual-field toxicity that accompanies its use. [4] [3]
(b) What intracranial lesion requires surveillance in tuberous sclerosis, what complication does it cause, and how is the growing lesion treated? (4 marks)
The subependymal giant cell astrocytoma requires surveillance with magnetic resonance imaging at intervals, because as it grows near the foramen of Monro it can cause obstructive hydrocephalus and raised intracranial pressure. The growing lesion is treated with the mTOR inhibitor everolimus, which reduced lesion volume in the phase-three EXIST-1 trial and is now standard of care. [5] [3]
(c) Name four major diagnostic criteria for tuberous sclerosis complex. (3 marks)
Major criteria include three or more hypomelanotic macules, three or more angiofibromas or a fibrous cephalic plaque, the shagreen patch, cortical dysplasia or cortical tubers, subependymal nodules, the subependymal giant cell astrocytoma, cardiac rhabdomyoma, and renal angiomyolipoma. A definite clinical diagnosis needs two major or one major plus two minor criteria, or a pathogenic TSC1 or TSC2 variant. [4] [3]
References
- [1]National Institutes of Health Consensus Development Panel Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol, 1988.PMID 3128965
- [2]Gutmann DH; Ferner RE; Listernick RH; et al Neurofibromatosis type 1. Nat Rev Dis Primers, 2017.PMID 28230061
- [3]Northrup H; Aronow ME; Bebin EM; et al Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol, 2021.PMID 34399110
- [4]Krueger DA; Northrup H; International Tuberous Sclerosis Complex Consensus Group Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol, 2013.PMID 24053983
- [5]Franz DN; Belousova E; Sparagana S; et al Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 2013.PMID 23158522
- [6]Gutmann DH; Aylsworth A; Carey JC; et al The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA, 1997.PMID 9207339